These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26020272)

  • 1. Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
    Zhao X; Wang S; Wu J; Li X; Wang X; Gao Z; Wu W; Wang H; Wang J; Qian J; Ma K; Li H; Han B; Bai C; Li Q; Liu W; Lu D
    PLoS One; 2015; 10(5):e0129232. PubMed ID: 26020272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
    Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Liu L; Zhou F; Ren S; Chen X; Li X; Li W; Zhou C
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):e339-46. PubMed ID: 25131817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
    Chen X; Zhang L; Ren S; Li X; Zhou F; Li W; Gao G; He Y; Zhou C
    Med Oncol; 2014 Apr; 31(4):865. PubMed ID: 24535606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
    Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B
    Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
    Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
    Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
    Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
    Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
    Luo J; Leaw SJ; Xu Y; Zheng D
    Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
    Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
    Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
    Trani L; Myerson J; Ashley S; Young K; Sheri A; Hubner R; Puglisi M; Popat S; O'Brien ME
    Lung Cancer; 2010 Nov; 70(2):200-4. PubMed ID: 20227784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.
    Zhao X; Wang X; Wu W; Gao Z; Wu J; Garfield DH; Wang H; Wang J; Qian J; Li H; Jin L; Li Q; Han B; Lu D; Bai C
    Cancer; 2012 Jul; 118(14):3587-98. PubMed ID: 22072145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
    Greco FA; Spigel DR; Kuzur ME; Shipley D; Gray JR; Thompson DS; Burris HA; Yardley DA; Pati A; Webb CD; Gandhi JG; Hainsworth JD
    Clin Lung Cancer; 2007 Sep; 8(8):483-7. PubMed ID: 17922972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
    Li XD; Han JC; Zhang YJ; Li HB; Wu XY
    Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.